Assessment of the Quality of Life of Multiple Sclerosis Patients Treated With Ofatumumab in Real-life in France

SEPROS is a non-interventional study, based on primary data collection of MS adult
patients who initiated ofatumumab as per neurologist practice and regardless of the study
protocol. This is a non-interventional, prospective (primary data), multicenter study conducted in
metropolitan France. The primary objective of this study is to describe the quality of
life of MS patients after initiation of treatment with ofatumumab.

In order to form a representative sample of MS patients taking into account the terms of
care in France, free or practicing neurologists in healthcare institutions (public or
private) in different regions of France will be selected to participate in this study.

The study will enroll adult patients with MS who initiated ofatumumab according to the
physician's advice and independently of the study. Patients will be followed from
initiation of ofatumumab either until (i) 12 months (± 1month) after initiation of
ofatumumab (End of Study), or until (ii) discontinuation of treatment with ofatumumab
prior to the completion of the 12-month follow-up (early termination); whichever occurs
first (end of study or early termination).